论文部分内容阅读
胃粘膜相关淋巴样组织(MALT)型结外边缘区B细胞淋巴瘤发病机制主要与幽门螺杆菌(H.pylori)感染有关,目前认为根治H.pylori治疗已成为胃粘膜相关淋巴样组织淋巴瘤的一线治疗。然而,抗H.pylori治疗不能使胃MALT淋巴瘤100%完全缓解,即使完全缓解后仍有复发的可能。随着研究的深入,哪些患者更能从抗H.pylori治疗中受益,抗H.pylori治疗后随访是目前研究的热点。此文对胃MALT淋巴瘤与H.pylori的关系,抗H.pylori治疗的有效预测、随访作一综述。
The pathogenesis of gastric mucosa-associated lymphoid tissue (MALT) type extranodal marginal zone B-cell lymphoma is mainly related to H. pylori infection. At present, the treatment of H. pylori has become the gastric mucosa-associated lymphoid tissue lymphoma First-line treatment. However, anti-H. pylori treatment did not completely remission 100% of gastric MALT lymphoma, even after complete remission. With further research, which patients benefit more from anti-H.pylori treatment, follow-up after anti-H.pylori treatment is currently the hot spot. This article reviews the relationship between gastric MALT lymphoma and H. pylori, the effective prediction of anti-H. pylori treatment, and follow-up.